Tendon, ligament, cartilage, bone and joint recovery — what the evidence really shows.
Injuries & Orthopedics is the musculoskeletal hub — tendon, ligament, cartilage, bone and joint recovery, the highest-search, highest-intent peptide cluster. It is also where the gap between promise and proof is widest: the most popular repair peptides are backed mostly by animal studies. We cover the mechanisms, the real evidence grade, and the anti-doping reality for athletes.
Wound healing is one of the few peptide areas with genuine human controlled-trial data — but it is narrow, topical, and concentrated in chronic wounds. A clinical-editorial ranking of GHK-Cu, thymosin β4, LL-37 and BPC-157 by what the evidence actually supports in 2026.
An evidence-graded review of the peptides marketed for wrist sprains, tenosynovitis, TFCC tears and carpal tunnel syndrome. The honest 2026 verdict: no human RCT — indeed essentially no human data of any kind — exists; the case is entirely preclinical (rat tendon and sciatic-nerve models), and conventional care has the far stronger human evidence.
Injuries & OrthopedicsA clinical, evidence-first ranking of the peptides most promoted for healing surgical incisions and preventing scars — separating genuine human topical-wound data from animal-only signals and marketing.
Injuries & OrthopedicsTendon is the single best-studied musculoskeletal target for repair peptides — yet no human RCT exists for any peptide in any tendinopathy. We rank BPC-157, TB-500/thymosin β-4 and GHK-Cu strictly by the real evidence.
Injuries & OrthopedicsA clinical, evidence-first look at the peptides pitched for rotator-cuff tears, labral injury and shoulder tendinopathy — BPC-157, TB-500/thymosin β-4, and GHK-Cu — and why all three are graded C (preclinical only) for the shoulder.
Injuries & OrthopedicsAn evidence-graded look at the peptides marketed for rotator-cuff tears and repair recovery — BPC-157, TB-500/Thymosin β4 and GHK-Cu — separating a single unpublished rat abstract and animal mechanism from anything resembling human proof.
Injuries & OrthopedicsA clinical, evidence-graded ranking of the peptides marketed for post-surgical recovery — thymosin alpha-1, thymosin β4/TB-500, GHK-Cu and BPC-157 — separating the one with human surgical RCT data from the rest, which are topical, negative, or preclinical only.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for osteoarthritis and joint degeneration. The honest 2026 verdict: the strongest human data belongs not to any joint-repair peptide but to GLP-1 metabolic drugs that relieve knee-OA pain by removing mechanical load.
Injuries & OrthopedicsA clinical, evidence-graded ranking of peptide drugs for osteoporosis — from the FDA-approved PTH-receptor anabolics with Grade A fracture-reduction RCTs to salmon calcitonin's regulatory demotion and the entirely unproven grey-market 'bone peptides.'
Injuries & OrthopedicsA clinical, evidence-graded ranking of the peptides studied for nerve injury and neuropathy — ARA-290, Cerebrolysin, BPC-157 and Cortagen — separating genuine human RCT data from animal-only signal.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for whiplash and neck soft-tissue injury. The honest 2026 verdict: there is no human evidence — no RCT, cohort, or registered trial — for any peptide in the cervical spine; the strongest case tops out at rat ligament and tendon models.
Injuries & OrthopedicsA clinical, evidence-graded review of the peptides marketed for hamstring pulls, calf and quad strains, and muscle tears — where the animal data are genuinely muscle-specific, and why no completed human trial yet proves any of them heals a strain.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for muscle growth and lean mass — follistatin, CJC-1295, ipamorelin, MGF and IGF-1 LR3. The honest 2026 verdict: no peptide has Grade A human muscle-outcome data, and every one is prohibited in sport by WADA.
Injuries & OrthopedicsA clinical, evidence-graded review of the peptides marketed for sprains, MCL tears and ACL injury — where the rat data are genuinely ligament-specific, and why no human trial yet proves any of them heals a torn ligament.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for meniscus tears, ligament sprains, tendinopathy and cartilage wear. The honest 2026 verdict: no peptide has a placebo-controlled human knee trial — the strongest case is preclinical (rat surgery models) plus one uncontrolled human case series.
Injuries & OrthopedicsA clinical, evidence-graded review of the peptides marketed for joint health and joint pain — BPC-157, TB-500/thymosin β-4, GHK-Cu and ARA-290 — ranked honestly by the strength of their human vs preclinical data.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed to 'injury-proof' tendons and ligaments. The honest 2026 verdict: prevention is the single most speculative claim in the peptide literature — no human prevention RCT, and no controlled animal prevention study, exists for any candidate.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for hip labral tears, femoroacetabular impingement, gluteal tendinopathy (GTPS) and hip bursitis. The honest 2026 verdict: no peptide has a human hip trial — the evidence tops out at animal models, while exercise and PRP hold the real human RCT data.
Injuries & OrthopedicsA clinical, evidence-graded ranking of the peptides studied for bone — from the FDA-approved PTH-class anabolics with Grade A fracture-prevention RCTs to the entirely preclinical regenerative peptides.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for endurance and aerobic performance — elamipretide (SS-31), MOTS-c and AOD-9604. The honest 2026 verdict: no peptide is proven to raise VO₂max or race performance in healthy humans, the category is preclinical-dominant, and MOTS-c is WADA-banned at all times.
The honest answer is that the evidence is almost entirely preclinical. Peptides such as BPC-157 and TB-500 show consistent tendon, ligament and muscle-healing effects in rodent models, with coherent mechanisms involving angiogenesis and cell migration. But there are no completed human randomized controlled trials demonstrating they heal injuries in people — the first such trial only recently began. We grade these compounds C (preclinical only) and are explicit that human healing claims extrapolate from animal data.
Most are not FDA-approved and exist in a regulatory gray zone. Several were placed on the FDA 503A Category 2 list in 2023, removed in April 2026 because the nominations were withdrawn (not because they were found safe), and are scheduled for advisory-committee review in July 2026 — none of which authorizes compounding. They are sold as "research chemicals not for human use." Legal status changes; we date-stamp every regulatory statement and link the primary source.
Athletes face a specific, serious risk: many tissue-repair peptides, including BPC-157 and TB-500, are prohibited at all times under the WADA Prohibited List (category S0, non-approved substances), with no therapeutic use exemption available. They are detectable in testing and have triggered real sanctions and bans. The NFL, UFC and US Department of Defense also prohibit them. Any WADA-tested or military athlete should treat these compounds as banned.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
